ANTI-VACCINIA VIRUS ANTIGEN ANTIBODIES AND RELATED COMPOSITIONS AND METHODS
Provided are antibodies that specifically bind to Vaccinia Virus B5 antigen (VV B5). In certain embodiments, the anti-VV B5 antibodies are humanized antibodies. Fusion proteins and conjugates comprising such antibodies are also provided. Pharmaceutical compositions comprising the antibodies, fusion...
Saved in:
Main Authors | , , , , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
22.09.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Provided are antibodies that specifically bind to Vaccinia Virus B5 antigen (VV B5). In certain embodiments, the anti-VV B5 antibodies are humanized antibodies. Fusion proteins and conjugates comprising such antibodies are also provided. Pharmaceutical compositions comprising the antibodies, fusion proteins and conjugates of the present disclosure are also provided, as are methods of using such compositions, e.g., for therapy, in vivo imaging and/or the like. In certain aspects, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual, wherein the individual comprises cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cells by VV B5 antigens expressed on the surface of the infected cells.
L'invention concerne des anticorps qui se lient de manière spécifique à l'antigène B5 du virus de la vaccine (VV B5). Dans certains modes de réalisation, les anticorps anti-VV B5 sont des anticorps humanisés. L'invention concerne également des protéines de fusion et des conjugués comprenant de tels anticorps. L'invention concerne également des compositions pharmaceutiques comprenant les anticorps, des protéines de fusion et des conjugués selon la présente invention, ainsi que des procédés d'utilisation de telles compositions, par exemple, pour une thérapie, une imagerie in vivo et/ou similaire. Selon certains aspects, l'invention concerne des méthodes comprenant l'administration d'un anticorps, une protéine de fusion ou un conjugué selon la présente invention à un individu, l'individu présentant des cellules infectées par un VV, et l'anticorps, la protéine de fusion ou le conjugué étant dirigés contre les cellules infectées par des antigènes du VV B5 exprimés sur la surface des cellules infectées. |
---|---|
AbstractList | Provided are antibodies that specifically bind to Vaccinia Virus B5 antigen (VV B5). In certain embodiments, the anti-VV B5 antibodies are humanized antibodies. Fusion proteins and conjugates comprising such antibodies are also provided. Pharmaceutical compositions comprising the antibodies, fusion proteins and conjugates of the present disclosure are also provided, as are methods of using such compositions, e.g., for therapy, in vivo imaging and/or the like. In certain aspects, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual, wherein the individual comprises cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cells by VV B5 antigens expressed on the surface of the infected cells.
L'invention concerne des anticorps qui se lient de manière spécifique à l'antigène B5 du virus de la vaccine (VV B5). Dans certains modes de réalisation, les anticorps anti-VV B5 sont des anticorps humanisés. L'invention concerne également des protéines de fusion et des conjugués comprenant de tels anticorps. L'invention concerne également des compositions pharmaceutiques comprenant les anticorps, des protéines de fusion et des conjugués selon la présente invention, ainsi que des procédés d'utilisation de telles compositions, par exemple, pour une thérapie, une imagerie in vivo et/ou similaire. Selon certains aspects, l'invention concerne des méthodes comprenant l'administration d'un anticorps, une protéine de fusion ou un conjugué selon la présente invention à un individu, l'individu présentant des cellules infectées par un VV, et l'anticorps, la protéine de fusion ou le conjugué étant dirigés contre les cellules infectées par des antigènes du VV B5 exprimés sur la surface des cellules infectées. |
Author | SMAZYNSKI, JULIAN VAN DUIJNHOVEN, SANDER MARTINUS JOHANNES BERGQVIST, JAN PETER NELSON, BRAD LIN, KUO-SHYAN BENARD, FRANCOIS CUMMINS, EMMA J TWUMASI-BOATENG, KWAME KWOK, YIN YU EUNICE ROUSSEAU, JULIE MARIE |
Author_xml | – fullname: BENARD, FRANCOIS – fullname: ROUSSEAU, JULIE MARIE – fullname: VAN DUIJNHOVEN, SANDER MARTINUS JOHANNES – fullname: NELSON, BRAD – fullname: TWUMASI-BOATENG, KWAME – fullname: SMAZYNSKI, JULIAN – fullname: BERGQVIST, JAN PETER – fullname: CUMMINS, EMMA J – fullname: KWOK, YIN YU EUNICE – fullname: LIN, KUO-SHYAN |
BookMark | eNrjYmDJy89L5WTwdvQL8dQNc3R29vTzdFQI8wwKDVYAibm7-oFpJ38XT1eQkItCkKuPY4iri4Kzv2-Af7BniKe_H0TC1zXEw98lmIeBNS0xpziVF0pzMyi4uYY4e-imFuTHpxYXJCan5qWWxDs7GhsZGloamzoaGhOhBABSei7g |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | ANTICORPS ANTI-ANTIGENE DU VIRUS DE LA VACCINE ET COMPOSITIONS ET PROCEDES ASSOCIES |
ExternalDocumentID | CA3211935A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_CA3211935A13 |
IEDL.DBID | EVB |
IngestDate | Fri Sep 27 05:30:54 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English French |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_CA3211935A13 |
Notes | Application Number: CA20223211935 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220922&DB=EPODOC&CC=CA&NR=3211935A1 |
ParticipantIDs | epo_espacenet_CA3211935A1 |
PublicationCentury | 2000 |
PublicationDate | 20220922 |
PublicationDateYYYYMMDD | 2022-09-22 |
PublicationDate_xml | – month: 09 year: 2022 text: 20220922 day: 22 |
PublicationDecade | 2020 |
PublicationYear | 2022 |
RelatedCompanies | ADMARE THERAPEUTICS SOCIETY UVIC INDUSTRY PARTNERSHIPS INC PROVINCIAL HEALTH SERVICES AUTHORITY |
RelatedCompanies_xml | – name: UVIC INDUSTRY PARTNERSHIPS INC – name: PROVINCIAL HEALTH SERVICES AUTHORITY – name: ADMARE THERAPEUTICS SOCIETY |
Score | 3.4183125 |
Snippet | Provided are antibodies that specifically bind to Vaccinia Virus B5 antigen (VV B5). In certain embodiments, the anti-VV B5 antibodies are humanized... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
Title | ANTI-VACCINIA VIRUS ANTIGEN ANTIBODIES AND RELATED COMPOSITIONS AND METHODS |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220922&DB=EPODOC&locale=&CC=CA&NR=3211935A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNp-L8Ig_St-JouoY9FOnSzlXpB2tX9jaWLoW9dMNV_Pe9hG36ok8JOQjh4O5-l-R-B_BEVZ8jKhdmhWjEtGVvaQpaUnMhqcOETTEka7bP2BlP7bdZf9aC1b4WRvOEfmlyRLSoEu290f5683OJ5eu_ldtnscKl9csod31jlx1bVm9gWYY_dIM08RNucO5yz4gnLlVMZrTvYaJ0hCiaKWMIiqEqStn8jiijczhOcbO6uYCWrDtwyveN1zpwEu3eu3G6M73tJbx7cR6ahcd5GIceKcLJNCNq7TWI9ThMFLTDqU9UHwz0SIQnUZpkoa4U1oIoyMeJn10BGQU5H5t4qvlBA3PuHc5Pr6Fdr2t5A2TgVEshRMlK5tgLibksEwPJKkQk0kHk14Xun9vc_iO7gzOlSvUrwrLuod18fMoHDL2NeNRK-waMpYFC |
link.rule.ids | 230,309,783,888,25576,76876 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da8IwED_Ejbm3zW3MffZh9K1MmtrShzJqWtdO-4HW4puYGsGXKtqxf3-XUN1etqeEHIRwcHe_S3K_A3ghos8R4QtthWhEM3h3qTFSEG3BiWkxg2BIlmyfsRlMjY9Zb9aA9aEWRvKEfklyRLSoAu29kv56-3OJ5cm_lftXtsalzdsgczy1zo51vWvruur1HT9NvISqlDrUVeOxQwSTGem5mCidIMK2hDH4eV8UpWx_R5TBBZymuFlZXUKDl21o0UPjtTacRfV7N05r09tfwdCNs1DLXUrDOHSVPBxPJ4pYe_djOfYTAe1w6imiDwZ6JIUmUZpMQlkpLAWRnwWJN7kGZeBnNNDwVPOjBubUPZ6f3ECz3JT8FhTbXC0ZY4VVWKax4JjLWszm1goRCTcR-XWg8-c2d__InqEVZNFoPgrj4T2cC7WKHxK6_gDNavfJHzEMV-xJKvAbyF6ENQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=ANTI-VACCINIA+VIRUS+ANTIGEN+ANTIBODIES+AND+RELATED+COMPOSITIONS+AND+METHODS&rft.inventor=BENARD%2C+FRANCOIS&rft.inventor=ROUSSEAU%2C+JULIE+MARIE&rft.inventor=VAN+DUIJNHOVEN%2C+SANDER+MARTINUS+JOHANNES&rft.inventor=NELSON%2C+BRAD&rft.inventor=TWUMASI-BOATENG%2C+KWAME&rft.inventor=SMAZYNSKI%2C+JULIAN&rft.inventor=BERGQVIST%2C+JAN+PETER&rft.inventor=CUMMINS%2C+EMMA+J&rft.inventor=KWOK%2C+YIN+YU+EUNICE&rft.inventor=LIN%2C+KUO-SHYAN&rft.date=2022-09-22&rft.externalDBID=A1&rft.externalDocID=CA3211935A1 |